Vijaya Diagnostic Centre Ltd. (IN:VIJAYA)
:VIJAYA
Want to see IN:VIJAYA full AI Analyst Report?
Top Page
Vijaya Diagnostic Centre Ltd.
(VIJAYA)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹1,483.00
▲(40.52% Upside)
Action:Reiterated
Date:05/12/26
The score is driven primarily by strong financial performance (solid growth and consistently high profitability). Technicals show a strong uptrend but are extremely overbought, increasing pullback risk. Valuation is the main drag due to a high P/E and minimal dividend yield.
Positive Factors
Consistent Revenue Growth
Sustained top-line growth with acceleration into 2026 indicates expanding demand and successful market penetration. For a diagnostics firm, consistent revenue gains support fixed-cost absorption, justify capital reinvestment in labs/imaging, and underpin multi-quarter earnings resilience.
Negative Factors
Uneven Free Cash Flow Conversion
Volatile FCF conversion points to swings from capex timing or working-capital cycles that can strain liquidity in weaker revenue periods. This variability reduces predictability of internal funding for expansion and may force episodic external financing or slower organic rollouts.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sustained top-line growth with acceleration into 2026 indicates expanding demand and successful market penetration. For a diagnostics firm, consistent revenue gains support fixed-cost absorption, justify capital reinvestment in labs/imaging, and underpin multi-quarter earnings resilience.
Read all positive factors
Vijaya Diagnostic Centre Ltd. (VIJAYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹130.36B
Dividend Yield0.2%
Average Volume (3M)7.14K
Price to Earnings (P/E)52.6
Beta (1Y)0.64
Revenue Growth19.49%
EPS Growth20.50%
CountryIN
Employees2,053
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)14.77
Shares Outstanding102,724,940
10 Day Avg. Volume16,300
30 Day Avg. Volume7,139
Financial Highlights & Ratios
PEG Ratio2.57
Price to Book (P/B)9.51
Price to Sales (P/S)11.18
P/FCF Ratio103.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)21.81
Revenue Forecast (FY)₹9.69B
Vijaya Diagnostic Centre Ltd. Business Overview & Revenue Model
Company Description
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. It offers laboratory services, including clinical biochemistry, haematology and immune-haematology, clinical pathology, histopathology and cytopathology, microbio...
How the Company Makes Money
VIJAYA primarily earns revenue by delivering diagnostic services and charging fees per test or per scan. Its key revenue streams are (1) pathology: income from clinical laboratory tests (e.g., biochemistry, hematology, immunology/serology, microbi...
Vijaya Diagnostic Centre Ltd. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
78
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.31B | 8.14B | 6.81B | 5.48B | 4.59B | 4.62B |
| Gross Profit | 5.88B | 7.20B | 5.96B | 4.82B | 4.00B | 3.91B |
| EBITDA | 3.12B | 3.58B | 2.88B | 2.38B | 1.95B | 2.15B |
| Net Income | 1.52B | 1.73B | 1.43B | 1.19B | 846.32M | 1.10B |
Balance Sheet | ||||||
| Total Assets | 13.91B | 15.07B | 12.74B | 9.83B | 8.53B | 7.13B |
| Cash, Cash Equivalents and Short-Term Investments | 2.58B | 2.89B | 2.33B | 1.85B | 2.55B | 2.25B |
| Total Debt | 3.65B | 4.23B | 3.20B | 2.59B | 2.48B | 1.83B |
| Total Liabilities | 5.26B | 5.50B | 4.74B | 3.23B | 3.07B | 2.44B |
| Stockholders Equity | 8.65B | 9.57B | 7.96B | 6.57B | 5.45B | 4.68B |
Cash Flow | ||||||
| Free Cash Flow | 453.03M | 878.75M | 1.29B | 953.37M | 397.69M | 356.50M |
| Operating Cash Flow | 1.39B | 2.71B | 2.24B | 1.83B | 1.65B | 1.58B |
| Investing Cash Flow | -840.24M | -1.74B | -1.82B | -1.42B | -1.10B | -1.23B |
| Financing Cash Flow | -432.23M | -694.88M | -520.48M | -445.50M | -419.12M | -305.72M |
Vijaya Diagnostic Centre Ltd. Technical Analysis
Positive
1055.40
Price Trends
1052.20
Positive
1025.49
Positive
1026.34
Positive
Market Momentum
72.31
Positive
62.11
Neutral
31.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIJAYA, the sentiment is Positive. The current price of 1055.4 is below the 20-day moving average (MA) of 1210.61, above the 50-day MA of 1052.20, and above the 200-day MA of 1026.34, indicating a bullish trend. The MACD of 72.31 indicates Positive momentum. The RSI at 62.11 is Neutral, neither overbought nor oversold. The STOCH value of 31.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIJAYA.
Vijaya Diagnostic Centre Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹107.45B | 44.11 | ― | 0.21% | 23.64% | 29.96% | |
71 Outperform | ₹130.36B | 52.62 | ― | 0.20% | 19.49% | 20.50% | |
62 Neutral | ₹97.32B | 541.44 | ― | ― | 16.15% | -67.50% | |
61 Neutral | ₹26.43B | 2.94 | ― | ― | 18.18% | ― | |
58 Neutral | ₹18.25B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,259.15
331.02
35.67%
IN:HCG
HealthCare Global Enterprises Ltd.
627.00
31.04
5.21%
IN:KRSNAA
Krsnaa Diagnostics Limited
565.00
-78.84
-12.25%
IN:METROPOLIS
Metropolis Healthcare Ltd.
528.35
122.46
30.17%
IN:UNICHEMLAB
Unichem Laboratories Limited
369.25
-256.25
-40.97%
Vijaya Diagnostic Centre Ltd. Corporate Events
Vijaya Diagnostic Shareholders Clear Appointment of Two Independent Directors via Postal Ballot
May 11, 2026
Vijaya Diagnostic Centre Ltd. has announced that its shareholders have approved the appointment of Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola as independent directors, following a postal ballot process conducted via remote e-voting. T...
Vijaya Diagnostic Centre Seeks Shareholder Nod for New Independent Directors via Postal Ballot
Apr 9, 2026
Vijaya Diagnostic Centre has initiated a postal ballot process to seek shareholder approval for the appointment of two independent directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola. The move underscores the company’s efforts...
Vijaya Diagnostic Centre Shuts Trading Window Ahead of FY26 Results
Mar 28, 2026
Vijaya Diagnostic Centre has announced the closure of its trading window for designated persons and their immediate relatives starting April 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s own ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.